FDA Tests AI to Speed Up Cancer and Lung Cancer Trials

Getting new medications to patients who desperately need them is about to get faster, thanks to artificial intelligence.

The Food and Drug Administration announced Tuesday it's partnering with AstraZeneca and Amgen to test a new approach to clinical trials. Instead of waiting months or years to review data, the agency will monitor trial results in real time using AI-powered platforms.

AstraZeneca is testing a combination therapy for patients with aggressive lymphoma at MD Anderson Cancer Center and the University of Pennsylvania. Amgen is running trials for a small cell lung cancer treatment. Both trials will use a platform called Paradigm Health that processes data as it comes in.

The FDA is also asking the public to weigh in on expanding the program. Future uses could include AI systems that spot safety issues faster, help determine the right medication doses for individual patients, and identify people who could benefit from joining trials.

Clinical trials typically take years to complete, partly because data collection and analysis happens in stages. Researchers gather information, wait for scheduled review periods, then make adjustments based on what they learn. Each pause adds time between discovery and delivery.

The Ripple Effect

Real-time monitoring could transform how quickly promising treatments reach patients. When researchers can see safety signals and effectiveness data immediately, they can make faster decisions about moving forward or adjusting course.

The change matters most for people with serious illnesses who don't have years to wait. Aggressive cancers like the lymphoma in AstraZeneca's trial can progress rapidly. Every month saved in the approval process could mean saved lives.

AI can also help match the right patients to the right trials by analyzing medical records and identifying people who meet specific criteria. Many trials struggle to find enough participants, which slows down research even when a treatment shows promise.

The pilot program represents a shift in how the FDA approaches innovation. Rather than waiting for perfect systems, the agency is testing new tools with real trials and asking stakeholders for input along the way.

Two major pharmaceutical companies and leading cancer centers are already on board, suggesting the approach has support from researchers who run trials every day.

This is just the beginning of AI's role in bringing new treatments to patients who need them most.